Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

Annals of the Rheumatic Diseases

Volumn 72, Issue 1, 2013, Pages 83-88

  Wagner, Carrie L ^a   Visvanathan, Sudha ^b   Elashoff, Michael ^c   McInnes, Iain B ^d   Mease, Philip J ^e   Krueger, Gerald G ^f   Murphy, Frederick T ^g   Papp, Kim ^h   Gomez Reino, Juan J ⁱ   Mack, Michael ^a   Beutler, Anna ^j   Gladman, Dafna ^j   Kavanaugh, Arthur ^k  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Elashoff Consulting LLC   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e Seattle Rhumatology Associates   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g Altoona Arthritis and Osteoporosis Center   (United States)

^h PROBITY MEDICAL RESEARCH   (Canada)

ⁱ UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN C3; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; GOLIMUMAB; HAPTOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 16; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PLACEBO; PROTEIN S 100; PROTEIN S100A12; PYRIDINOLINE; SERUM AMYLOID P; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY 20 PERCENT IMPROVEMENT SCORE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE REMODELING; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSORIASIS AREA AND SEVERITY SCORE INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BONE REMODELING; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 84871085190     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201697     Document Type: Article

References (21)

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis; epidemiology, clinical features, course, and outcomes. Ann Rheum Dis 2005;64(Suppl. 2):ii14-17.
2. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241-9. (Pubitemid 36693144)
3. van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006;65:1551-7. (Pubitemid 44799664)
4. van Kuijk AW, Wijbrandts CA, Vinkenoog M, et al. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis 2010;69:301-4.
5. Xia L, Shen H, Xiao W, et al. Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine 2011;53:289-91.
6. Ribbens C, Martin y Porras M, Franchimont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6. (Pubitemid 34098433)
7. van Kuijk AW, DeGroot J, Koeman RC, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One 2010;5:e12556.
8. Grisar J, Bernecker PM, Aringer M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6. (Pubitemid 34755610)
9. Dalbeth N, Pool B, Smith T, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010;12:R164.
10. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
11. Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis 2012;71:674-80.
12. Visvanathan S, Rahman MU, Keystone E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther 2010;12:R211.
13. Pedersen SJ, Hetland ML, Sorensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol 2010;29:1301-9.
14. Hashimoto J, Garnero P, van der Heijde D, et al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol 2009;19:273-82.
15. Hashimoto J, Garnero P, van der Heijde D, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 2011;21:10-15.
16. Warstat K, Hoberg M, Rudert M, et al. Transforming growth factor beta1 and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:270-5.
17. Cho ML, Jung YO, Kim KW, et al. IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp Mol Med 2008;40:237-45.
18. Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17 positive mast cells contribute to synovial inflammation in spondyloarthritis. Arthritis Rheum 2012;64:99-109.
19. Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003;42:1383-9. (Pubitemid 37407031)
20. Gomez R, Conde J, Scotece M, et al. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 2011;7:528-36.
21. Otero M, Lago R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1198-201. (Pubitemid 44277396)